[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% +18%
1 Month: XX% +17%
6 Months: XX% +11%
1 Year: XX% +26%
1-Year High: XX% on 2025-06-04
1-Year Low: XX% on 2024-12-14
Most Supportive Themes
- Positive Outlook on JNJ's Pharma Business: (25%) Analysts are optimistic about Johnson & Johnson's (JNJ) pharmaceutical business, citing strong drug sales and potential for growth. This theme is supported by multiple news articles and social posts.
- JNJ's Dividend and Financial Stability: (15%) Several posts highlight JNJ's consistent dividend payouts and financial stability, making it an attractive investment for income-focused investors. This is a recurring theme in financial discussions.
- Positive Developments in Ulcerative Colitis Treatment: (10%) Positive data from Icotrokinra and Tremfya in ulcerative colitis trials are being highlighted, suggesting potential for a standout combination of therapeutic benefit and a favorable safety profile. This is a key area of focus for the company.
Most Critical Themes
- Talc Lawsuit and Legal Challenges: (30%) A recent jury verdict ordered Johnson & Johnson to pay a significant amount in a talc-related cancer case, raising concerns about ongoing litigation and potential financial impacts. This is a major headwind for the company.
- Concerns about Tylenol and Autism: (20%) Reports and internal records suggest that Johnson & Johnson may have been aware of potential links between Tylenol and autism, leading to criticism and scrutiny. This is a significant reputational risk.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXXXXXX | XX% | XXXXXXX | XX% | XXXXXX | X% |
| X | X% | X | X% | XXX | X% | |
| YouTube | XXXXX | X% | XXXXXX | X% | XXXXXX | X% |
| TikTok | XXXXX | X% | XXXXXX | X% | XXX | X% |
| News | XXXXX | X% | XXXXX | X% | XX | X% |
| Total | XXXXXXX | XX% | XXXXXXX | XX% | XXXXXX | X% |